We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab
Read MoreHide Full Article
Valneva’s (VALN - Free Report) shares surged 24.3% on Nov 10, after the company announced that it has entered into an advance purchase agreement (APA) with the European Commission (EC) for the supply of its inactivated COVID-19 vaccine candidate, VLA2001.
Although the APA has been approved by the EC, it is currently under final review by the member states of the European Union (EU), providing them the possibility to secure up to 60 million doses of the company’s COVID-19 vaccine.
Per the APA, Valneva would supply approximately 27 million doses of VLA2001 to the member states of the EU in 2022. The APA will also allow these member states to procure additional purchases of up to 33 million doses of the COVID vaccine in 2023, including the possibility to adapt the vaccine to new COVID-19 variant strains.
The delivery of the vaccine supply by the company, which is anticipated to begin next April, is subject to approval of the vaccine candidate by the European Medicines Agency (“EMA”). The EMA is expected to initiate a rolling review of VLA2001 in the upcoming few weeks.
Valneva’s shares have rallied 77.3% so far this year in comparison with the industry’s 1.4% growth.
Image Source: Zacks Investment Research
The APA with Valneva is one of the many agreements undertaken by the EC to purchase potential COVID-19 vaccines. It has already inked similar deals with multiple companies like AstraZeneca (AZN - Free Report) , Moderna (MRNA - Free Report) and Pfizer (PFE - Free Report) for COVID-19 vaccines.
Last month, the company announced positive top-line data from the pivotal phase III study Cov-Compare (VLA2001-301) comparing Valneva’s VLA2001 against AstraZeneca’s COVID vaccine AZD1222. Data from the study demonstrated the superiority of VLA2001 over the AstraZeneca vaccine. The study achieved both co-primary endpoints two weeks after the second vaccination. VLA2001 produced superior neutralizing antibody titer levels than AZD1222 and VLA2001 demonstrated the same effectiveness as AZD1222 in neutralizing antibody seroconversion rates above 95%.
Though Valneva’s COVID-19 vaccine holds potential, it faces stiff competition from the COVID-19 vaccines developed by AstraZeneca, Moderna and Pfizer, which are already approved in the EU and are catering to this market. In fact, these vaccines have also been granted emergency use listing by the World Health Organizationand have already been administered to billions of people across the globe.
Image: Bigstock
Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab
Valneva’s (VALN - Free Report) shares surged 24.3% on Nov 10, after the company announced that it has entered into an advance purchase agreement (APA) with the European Commission (EC) for the supply of its inactivated COVID-19 vaccine candidate, VLA2001.
Although the APA has been approved by the EC, it is currently under final review by the member states of the European Union (EU), providing them the possibility to secure up to 60 million doses of the company’s COVID-19 vaccine.
Per the APA, Valneva would supply approximately 27 million doses of VLA2001 to the member states of the EU in 2022. The APA will also allow these member states to procure additional purchases of up to 33 million doses of the COVID vaccine in 2023, including the possibility to adapt the vaccine to new COVID-19 variant strains.
The delivery of the vaccine supply by the company, which is anticipated to begin next April, is subject to approval of the vaccine candidate by the European Medicines Agency (“EMA”). The EMA is expected to initiate a rolling review of VLA2001 in the upcoming few weeks.
Valneva’s shares have rallied 77.3% so far this year in comparison with the industry’s 1.4% growth.
The APA with Valneva is one of the many agreements undertaken by the EC to purchase potential COVID-19 vaccines. It has already inked similar deals with multiple companies like AstraZeneca (AZN - Free Report) , Moderna (MRNA - Free Report) and Pfizer (PFE - Free Report) for COVID-19 vaccines.
Last month, the company announced positive top-line data from the pivotal phase III study Cov-Compare (VLA2001-301) comparing Valneva’s VLA2001 against AstraZeneca’s COVID vaccine AZD1222. Data from the study demonstrated the superiority of VLA2001 over the AstraZeneca vaccine. The study achieved both co-primary endpoints two weeks after the second vaccination. VLA2001 produced superior neutralizing antibody titer levels than AZD1222 and VLA2001 demonstrated the same effectiveness as AZD1222 in neutralizing antibody seroconversion rates above 95%.
Though Valneva’s COVID-19 vaccine holds potential, it faces stiff competition from the COVID-19 vaccines developed by AstraZeneca, Moderna and Pfizer, which are already approved in the EU and are catering to this market. In fact, these vaccines have also been granted emergency use listing by the World Health Organizationand have already been administered to billions of people across the globe.
Valneva SE Sponsored ADR Price
Valneva SE Sponsored ADR price | Valneva SE Sponsored ADR Quote
Zacks Rank
Valneva currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.